JP2005516946A5 - - Google Patents

Download PDF

Info

Publication number
JP2005516946A5
JP2005516946A5 JP2003554189A JP2003554189A JP2005516946A5 JP 2005516946 A5 JP2005516946 A5 JP 2005516946A5 JP 2003554189 A JP2003554189 A JP 2003554189A JP 2003554189 A JP2003554189 A JP 2003554189A JP 2005516946 A5 JP2005516946 A5 JP 2005516946A5
Authority
JP
Japan
Prior art keywords
present
tegaserod
granulation
formulations
minutes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003554189A
Other languages
English (en)
Japanese (ja)
Other versions
JP4718776B2 (ja
JP2005516946A (ja
Filing date
Publication date
Priority claimed from EP01403339A external-priority patent/EP1321142A1/en
Application filed filed Critical
Publication of JP2005516946A publication Critical patent/JP2005516946A/ja
Publication of JP2005516946A5 publication Critical patent/JP2005516946A5/ja
Application granted granted Critical
Publication of JP4718776B2 publication Critical patent/JP4718776B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003554189A 2001-12-21 2002-12-20 5ht4部分アゴニスト医薬組成物 Expired - Fee Related JP4718776B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01403339A EP1321142A1 (en) 2001-12-21 2001-12-21 Solid pharmaceutical composition for oral administration of Tegaserod
EP01403339.3 2001-12-21
PCT/EP2002/014674 WO2003053432A1 (en) 2001-12-21 2002-12-20 5ht4 partial agonist pharmaceutical compositions

Publications (3)

Publication Number Publication Date
JP2005516946A JP2005516946A (ja) 2005-06-09
JP2005516946A5 true JP2005516946A5 (enExample) 2006-01-19
JP4718776B2 JP4718776B2 (ja) 2011-07-06

Family

ID=8183045

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003554189A Expired - Fee Related JP4718776B2 (ja) 2001-12-21 2002-12-20 5ht4部分アゴニスト医薬組成物

Country Status (31)

Country Link
US (2) US20050106236A1 (enExample)
EP (2) EP1321142A1 (enExample)
JP (1) JP4718776B2 (enExample)
KR (1) KR100980144B1 (enExample)
CN (1) CN100464749C (enExample)
AR (1) AR037937A1 (enExample)
AT (1) ATE320807T1 (enExample)
AU (1) AU2002361198B2 (enExample)
BR (1) BR0215148A (enExample)
CA (1) CA2470668C (enExample)
CO (1) CO5640102A2 (enExample)
CY (1) CY1105559T1 (enExample)
DE (1) DE60210139T2 (enExample)
DK (1) DK1458377T3 (enExample)
EC (1) ECSP105163A (enExample)
EG (1) EG24194A (enExample)
ES (1) ES2258171T3 (enExample)
HU (1) HU226589B1 (enExample)
IL (2) IL162451A0 (enExample)
MX (1) MXPA04006157A (enExample)
MY (1) MY139546A (enExample)
NO (1) NO20042779L (enExample)
NZ (1) NZ533585A (enExample)
PE (1) PE20030872A1 (enExample)
PL (1) PL369509A1 (enExample)
PT (1) PT1458377E (enExample)
RU (1) RU2322978C2 (enExample)
SI (1) SI1458377T1 (enExample)
TW (1) TWI260221B (enExample)
WO (1) WO2003053432A1 (enExample)
ZA (1) ZA200404467B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2257869T3 (es) * 1998-08-21 2006-08-01 Novartis Ag Nueva formulacion oral para agonistas o antagonistas de 5-ht4.
KR101227626B1 (ko) 2003-01-28 2013-02-01 아이언우드 파마슈티컬스, 인코포레이티드 위장병 치료 방법 및 위장병 치료용 조성물
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20050119328A1 (en) * 2003-03-25 2005-06-02 Hetero Drugs Limited Novel crysalline forms of tegaserod maleate
WO2004104577A2 (en) * 2003-05-21 2004-12-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 4 (5-ht4)
PE20050253A1 (es) * 2003-07-24 2005-06-03 Novartis Ag Modificaciones estables de maleato de hidrogeno de tegaserod
EP1663182B2 (en) 2003-09-12 2019-11-20 Amgen Inc. RAPID DISSOLUTION FORMULATION OF CINACALCET HCl
US20050165085A1 (en) * 2003-12-16 2005-07-28 Marioara Mendelovici Polymorphic forms of tegaserod base and salts thereof
CZ298399B6 (cs) * 2005-05-02 2007-09-19 Zentiva, A. S. Zpusob prípravy 2-[(5-methoxy-1 H-indol-3-yl) methylen]-N-pentylkarbazimidamidu (tegaserodu)
US20070259052A1 (en) 2006-05-05 2007-11-08 Shire International Licensing B.V. Assay for lanthanum hydroxycarbonate
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CA2748607A1 (en) 2008-12-31 2010-07-08 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2014029983A1 (en) 2012-08-21 2014-02-27 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
ES2735992T3 (es) 2013-04-12 2019-12-23 Ardelyx Inc Compuestos de unión a NHE3 y procedimientos para inhibir el transporte de fosfatos
CN104922083B (zh) * 2015-04-15 2017-12-22 湖南尔康湘药制药有限公司 磺胺嘧啶片及其制备方法
WO2017064538A1 (en) * 2015-10-16 2017-04-20 Nobel Ilac Sanayii Ve Ticaret A.S. Pharmaceutical compositions of nilotinib hydrochloride
JP7292207B2 (ja) 2017-01-09 2023-06-16 アルデリックス, インコーポレイテッド 消化管障害を処置するために有用な化合物
EA201991676A1 (ru) 2017-01-09 2020-01-30 Арделикс, Инк. Ингибиторы nhe-опосредованного антипорта

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0820586A (ja) * 1994-07-05 1996-01-23 Sanwa Kagaku Kenkyusho Co Ltd 1−アザビシクロ[3.3.0]オクタン誘導体、その塩及び製法並びに用途
IL117438A (en) * 1995-03-16 2001-12-23 Lilly Co Eli Indazolecarboxamides, their preparation and pharmaceutical compositions containing them
JPH09194374A (ja) * 1995-11-14 1997-07-29 Taisho Pharmaceut Co Ltd 消化器疾患治療剤
DE69713948D1 (de) * 1996-04-23 2002-08-22 Janssen Pharmaceutica Nv Rasch-freisetzende pH-unabhängige feste Dosisformen enthaltend Cisaprid
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
ES2257869T3 (es) * 1998-08-21 2006-08-01 Novartis Ag Nueva formulacion oral para agonistas o antagonistas de 5-ht4.
US6465502B1 (en) * 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
WO2000057857A1 (en) * 1999-03-25 2000-10-05 Yuhan Corporation Rapidly disintegrable tablet for oral administration
UA72922C2 (uk) * 1999-08-03 2005-05-16 Ліллі Айкос Ллк ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ З <font face="Symbol">b</font>-КАРБОЛІНОМ (ВАРІАНТИ) ТА СПОСІБ ЛІКУВАННЯ СЕКСУАЛЬНОЇ ДИСФУНКЦІЇ

Similar Documents

Publication Publication Date Title
JP2005516946A5 (enExample)
JPH1072351A5 (enExample)
AU2002348983A1 (en) Heat activated durable styling compositions comprising saccharide type compounds and film forming agents
CA2463947A1 (en) Montelukast granule formulation
JP2003503454A5 (enExample)
NO20041452L (no) 17-beta-hydroksysteroid-dehydrogenase type 3-inhibitorer for behandling av androgenavhengige sykdommer.
NO20053115D0 (no) Fremgangsmate for fremstilling av 2&#39;-forgrenede nukleosider.
NO20042739L (no) Farmasoytiske sammensetninger av 5,6,14-triazatetracyklo(10.3.1.0(2,11).0(4,9))-heksadeca-2(11)3,5,7,9-pentan
EA200400928A1 (ru) Диспергируемая во рту фармацевтическая композиция агомелатина
NO20024293D0 (no) Flekkfjernende tyggegummi og konfektblandinger, og fremgangsmåter for fremstilling av de samme
NO20052058D0 (no) Behandling av influensa.
DK1545230T3 (da) Belagt tyggegummi
DK1499667T3 (da) Overtrækssammensætning til multiple hydrofile anvendelser
TR200003788A3 (tr) Yavas salimli oral dozaj bilesim.
WO2003075857A3 (en) Amino-methyl substituted tetracycline compounds
DE60334379D1 (de) Copolymerverbindung, diese enthaltende polymerzusammensetzung, bilderzeugungsverfahren und dieselbe benutzende bilderzeugungsvorrichtung
AP2004003154A0 (en) Novel perindopril salt and pharmaceutical compositions containing same.
IS6378A (is) Efnasambönd og samsetningar gegn dvergveirum, notkun þeirra til lyfjagerðar og efni til að framleiða þau
IS6956A (is) Sítrat salt af 5,8,14,-tríasatetrasýkló[10.3.1.02,11.04,9]-hexadeka-2(11),3,5,7,9-pentaen og lyfjafræðilegar samsetningar af því
JP2005509503A5 (enExample)
JP2002240244A5 (enExample)
NO20052807D0 (no) Fremgangsmate for fremstilling av aminosyrer
NO20052471D0 (no) Fremgangsmate for fremstilling av 3-metyltiopropanal.
NO20000456D0 (no) Fremgangsmåte for fremstilling av 1,2-dikloretan
ATE392644T1 (de) Alpha-(1&#39; -hydroxyalkyl)acrylate enthaltende beschichtungsmassen